2-(4-oxo-3-phenethyl-3,4-dihydroquinazolin-2-ylthio)acetonitrile

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-(4-oxo-3-phenethyl-3,4-dihydroquinazolin-2-ylthio)acetonitrile
• 英文别名: 2-[4-Oxo-3-(2-phenylethyl)quinazolin-2-yl]sulfanylacetonitrile
• 化学式: C₁₈H₁₅N₃OS
• 分子量: 321.403
• InChiKey: MMACHNZVYFLOHW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  81.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-苯基乙基异硫代氰酸酯 在 potassium carbonate 、 三乙胺 作用下， 以 乙醇 、 丙酮 为溶剂， 反应 2.0h， 生成 2-(4-oxo-3-phenethyl-3,4-dihydroquinazolin-2-ylthio)acetonitrile
  参考文献：
  名称：

  Design, synthesis and biological evaluation of some novel substituted 2-mercapto-3-phenethylquinazolines as antitumor agents

  摘要：

  A novel series of 2-(substituted thio)-3-phenethylquinazolin-4(3H)-one and 2-([5-mercapto-4-(substituted)-4H-1,2,4-triazol-3-yl)methylthio]-3-phenethylquinazolin-4(3H)-one (1-25) were designed, synthesized, and evaluated for their in vitro antitumor activity. A single dose (10 mu M) of the test compounds was used in the National Cancer Institute (NCI) 60 cell lines panel assay. Compound 2 showed sensible selective activities toward renal and breast cancer cell lines, whereas breast cancer cell lines showed moderate sensitivity to compound 13. At the same time, compound 22 yielded reasonable selective activities toward leukemia and non-small cell lung cancer cell lines. The results achieved can be used as a useful template for future development and further derivatization or modification to obtain more potent and selective antitumor agents.

  DOI：

  10.1007/s00044-013-0546-z

文献信息

• Design, synthesis and biological evaluation of some novel substituted 2-mercapto-3-phenethylquinazolines as antitumor agents
  作者：Amer M. Alanazi、Ibrahim A. Al-Suwaidan、Alaa A.-M. Abdel-Aziz、Menshawy A. Mohamed、Ahmad M. El_Morsy、Adel S. El-Azab

  DOI：10.1007/s00044-013-0546-z

  日期：2013.11

  A novel series of 2-(substituted thio)-3-phenethylquinazolin-4(3H)-one and 2-([5-mercapto-4-(substituted)-4H-1,2,4-triazol-3-yl)methylthio]-3-phenethylquinazolin-4(3H)-one (1-25) were designed, synthesized, and evaluated for their in vitro antitumor activity. A single dose (10 mu M) of the test compounds was used in the National Cancer Institute (NCI) 60 cell lines panel assay. Compound 2 showed sensible selective activities toward renal and breast cancer cell lines, whereas breast cancer cell lines showed moderate sensitivity to compound 13. At the same time, compound 22 yielded reasonable selective activities toward leukemia and non-small cell lung cancer cell lines. The results achieved can be used as a useful template for future development and further derivatization or modification to obtain more potent and selective antitumor agents.